HEALTHY LIFESTYLE · AUGUST 2018
TREATMENTS PUTTING
CHEMO IN THE BACKSEAT
CAR-T, or Chimeric Antigen Receptor T cell
therapy, is a personalized therapy in which
a patient’s own blood cells are removed
and reengineered in a lab to engage the
immune system to attack cancer. The Food
and Drug Administration first approved the
CAR-T therapy in 2017 for specific types of
lymphoma and leukemia after promising
results during clinical trials. Earlier this
year, Texas Oncology–Baylor Charles A.
Sammons Cancer, in collaboration with
Baylor University Medical Center, became
the second facility in the state to provide
groundbreaking FDA-approved CAR-T
therapy for large B-cell lymphoma.
Is chemotherapy
for cancer
treatment going
the way of 8-track
tapes and rotary
dial phones?
While that overstates the
situation, the trend away from
chemo is clear as cancer care is
c